MAR 20, 2014 11:00 AM PDT

Using brain imaging and biomarkers for diagnosis and investigation of Alzheimer's disease "The Alzheimer's Disease Neuroimaging Initiat

Presented at: Neuroscience
Speaker
  • Principle Investigator of the Alzheimer's Disease, Neuroimaging Initiative, Professor in Residence, Medicine, Psychiatry, and Neurology, University of California, San Francisco
    BIOGRAPHY

Abstract

Alzheimers disease (AD) is a neurodegenerative disorder producing cognitive impairment and dementia in millions of elders. Currently no treatment is effective to slow the progression of AD. Major obstacles to developing effective treatments are: 1) a reliance on clinical symptoms and a lack of biomarkers for diagnosis 2) uncertainty concerning which biomarkers are best to identify disease stage and to predict progression 3) lack of standardization and 4) absence of naturalistic data to provide a basis for clinical trial design, problem in the field. To address these issues ADNI was funded for a total of $140 million, as a public/private partnership between the National Institute of Aging and a consortium of pharmaceutical companies (including Swiss companies). The goal of ADNI (from 2004-present see ADNI-info.org) has been to standardize and determine the value of MRI and PET imaging together with blood and CSF biomarkers for disease modifying Alzheimers treatment trials. In our initial project (ADNI1), we longitudinally studied: MCI (n= 400); AD (n= 200); Controls (n= 220) with clinical visits, neuropsychological assessments, MRI (1.5 T), FDG PET, blood and urine, and CSF. About 300 subjects from ADNI 1 continue to be followed. We found that the rate of hippocampal atrophy had high statistical power for measuring change over time. Normal healthy elders with APOE4 and/or low CSF Aβ amyloid have worse memory scores and higher rates of hippocampal atrophy, consistent with the view that about 30% of healthy elders in their 70s have preclinical AD pathology. Similar ADNI-like projects, with similar methods, are underway in Australia, Japan, Europe, China, Taiwan, and Korea leading to the World Wide ADNI network. The Parkinsons Progressive Markers Initiative (PPMI) has been modeled after ADNI. ADNI 2 with 3Tesla MRI and F18 amyloid PET imaging with Florbetapir on an additional 150 controls, 100 normal subjects with cognitive complaints, 300 subjects with early MCI, 150 subjects with late MCI , 150 subjects with dementia due to AD. Thus a total of about 1700 subjects have been enrolled and are followed longitudinally. Whole genome sequencing on 800 subjects is available. All ADNI data is available to all scientists in the world, on USC/LONI/ADNI, without embargo. Blood and CSF samples can be requested. ADNI methods are now widely used in clinical treatment trials, and have led to the development of the new research criteria. Over 600 papers have been written on ADNI data and all scientists are encouraged to explore this rich data set and publish their results. It is expected that ADNI will substantially contribute to identifying accurate diagnostic techniques and effective treatments to slow the progression and prevent Alzheimers disease.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
MAR 20, 2014 11:00 AM PDT

Using brain imaging and biomarkers for diagnosis and investigation of Alzheimer's disease "The Alzheimer's Disease Neuroimaging Initiat

Presented at: Neuroscience

Specialty

Research And Development

Earth Science

University

Research

Health

Geography

North America50%

Asia50%

Registration Source

Website Visitors100%

Job Title

Medical Laboratory Technician100%

Organization

Academic Institution50%

Manufacturer - Other50%


Show Resources
Loading Comments...
Show Resources